Paraneoplastic erythroderma in a prostate cancer patient

Strahlenther Onkol. 2002 Jul;178(7):393-5. doi: 10.1007/s00066-002-0967-y.

Abstract

Background: Erythroderma is an inflammation of the skin, which can be triggered by various diseases as psoriasis, allergies, side effects of medication, infections or malignant tumors. Caused by these various etiologic possibilities patients require extensive diagnostic effort.

Patient: We report a case of a 71-year-old man presenting with an erythroderma of unknown etiology. Therapy with corticosteroids was not successful. A complete remission was reached by therapy with cyclosporine A, 350 mg/day. Finally, an increased prostate specific antigene (PSA) value was found and a prostate cancer was diagnosed in the patient.

Results: After definitive radiotherapy of the carcinoma (total dose 74 Gy, 5 x 2 Gy/week), the cyclosporine A was displaced without recurrence of erythroderma.

Conclusion: In this case, we consider the erythroderma to have been a paraneoplastic effect of the prostate carcinoma. In male patients with erythroderma an early PSA test should be performed.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood
  • Biopsy
  • Cyclosporine / therapeutic use
  • Dermatitis, Exfoliative / diagnosis*
  • Dermatitis, Exfoliative / drug therapy
  • Dermatitis, Exfoliative / etiology
  • Dermatitis, Exfoliative / pathology
  • Diagnosis, Differential
  • Humans
  • Male
  • Paraneoplastic Syndromes / diagnosis*
  • Paraneoplastic Syndromes / drug therapy
  • Paraneoplastic Syndromes / etiology
  • Paraneoplastic Syndromes / pathology
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / radiotherapy
  • Skin / pathology

Substances

  • Biomarkers, Tumor
  • Cyclosporine
  • Prostate-Specific Antigen